Showing results (21-30 of 829) with videos related to
Sort By:
Pageof 83
Oncotarget|February 15, 2011
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsBen Markman, Rodrigo Dienstmann, Josep TaberneroAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in OncologyElena Garralda, Rodrigo Dienstmann, Josep TaberneroFuture Oncology (London, England)|April 21, 2012
Panitumumab: a summary of clinical development in colorectal cancer and future directionsGuillem Argiles, Rodrigo Dienstmann, Elena Elez, et al.Clinical Colorectal Cancer|July 7, 2011
Development of molecular biomarkers in individualized treatment of colorectal cancerLeticia De Mattos-Arruda, Rodrigo Dienstmann, Josep TaberneroMolecular Oncology|December 23, 2011
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancerRodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, et al.Nature Reviews. Cancer|January 5, 2017
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancerRodrigo Dienstmann, Louis Vermeulen, Justin Guinney, et al.Cancer Treatment Reviews|February 24, 2017
The expanding role of immunotherapyJuan Martin-Liberal, María Ochoa de Olza, Cinta Hierro, et al.Cancer Chemotherapy and Pharmacology|March 28, 2015
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3Morten Mau-Sørensen, Christian Dittrich, Rodrigo Dienstmann, et al.Nature Reviews. Clinical Oncology|April 5, 2012
Molecular prescreening to select patient population in early clinical trialsJordi Rodón, Cristina Saura, Rodrigo Dienstmann, et al.Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.Pageof 83